

Supplementary Materials

Supplementary methods

Cloning of UCOE-SFFV-KRAB-dCas9-P2A-mcherry vector

UCOE-SFFV-KRAB-dCas9-P2A vector was created by ligating the AgeI-MluI restriction fragment containing the UCOE and SFFV promoter from UCOE-SFFV-dCas9-KRAB-BFP (Addgene, 85969) into the complementary fragment of pHR-SFFV-KRAB-dCas9-P2A-mCherry (Addgene, 60954)(52). UCOE-SFFV-KRAB-dCas9-P2A-mcherry lentivirus was transduced into cells in serum free media + 5ug/uL polybrene for 6 hours followed by addition of complete media (1:1).

gRNA design and cloning

The sgRNAs were designed with BsmB1 cut sites, cloned into the sgOpti vector (Addgene, 85681), and validated by sanger sequencing. The negative control sgRNA NC_chr1 targets a unique intergenic site of no known function on chromosome 1, and showed no significant functional effect in a prior CRISPRi screen.

Cells transduced with UCOE-SFFV-KRAB-dCas9-P2A-mcherry were FACS sorted twice on mCherry expression. sgRNAs (Supplementary Table S1) were designed against nucleosome free regions flanking GGAA repeat sites using the Broad institutes GPP sgRNA designer. sgRNAs with high on-target scores were chosen and cloned into the sgOpti vector (Addgene, 85681). Lentiviral sgRNA-containing sgOpti vectors were transduced into stably expressing dCas9-KRAB-mcherry cells and puromycin selected before collection after 8 days.

Immunofluorescence

Frozen sections of E13.5 *Hoxd13* WT, heterozygous, and knockout embryos (27) were formalin fixed, frozen in OCT and sectioned. Slides were thawed at RT, washed with PBS, blocked for 1 hour at room temperature (10% donkey serum + 0.2% triton) and incubated with the HOXD13 primary antibody in blocking buffer overnight at 4C. Slides washed with 0.2% triton PBS before addition of donkey anti-rabbit 488 secondary in blocking buffer for 1 hour at RT. After three more PBS + 0.2% triton washes 1:1000 DAPI (Fisher) was added. Images were taken using an inverted Olympus IX83 (Tokyo, Japan). CellSens Dimensions captured the images. For immunocytochemistry, cells were fixed in 4% paraformaldehyde for 15 minutes and permeabilized in 0.5% Triton in PBS for 10 minutes. After washes in PBS, cells were blocked for 1 hour at RT in 0.2% BSA + 5% Goat Serum and then incubated either HOXD13 or IgG or 1 hour at RT in blocking buffer. Following 3 washes, a fluorescent secondary antibody was added and incubated for 1 hour at RT, followed by washes and DAPI (1:10 000) incubation. Images were taken on a Lecia DMi8 microscope using the Lecia software.

Mapping mouse enhancers to human

To map mouse enhancer sites in the regulatory HOXD domain the UCSC LIFTOVER tool was used to go from mm9 to hg19. Five developmental enhancer locations mapped (hg19): Island I (chr2:176124212-176134930), Island II (chr2:176237060-176246196), Island III (chr2:176423732-176424979), Island IV (chr2:176503826-176503873), Island V (chr2:176549574-176555217). PHE GGAA coordinates (hg19): chr2:176268550-176268900 (36).

Bru-seq/RNA-seq and analysis

Cell line samples were prepared as described previously (28). Bru-seq was performed on A673 and CHLA10 cells following HOXD13 knockdown. In brief, 72 hours after doxycycline addition to either shNS or shHOXD13#1 cells bromouridine (2mM; Sigma) was added for 30 minutes. Nascent RNA was immunoprecipitated out and cDNA libraries were prepared and sequenced using an Illumina HiSeq 2500 for 50-bp single-end reads at the University of Michigan Sequencing Core. Reads were processed, mapped (hg38), and quantified using the Bru-seq analysis pipeline (28). Poly(A)-capture RNA-seq was performed for TC32 HOXD13 knockdown cells. Libraries were prepared with NEBNext Ultra II RNA Library Prep kit and Paired end 150 bp sequencing was performed on a Novaseq600 by Novogene. Adapter Trimming was performed using Trim Galore (Babraham Institute). Trimmer reads were aligned to GRCh38 using the STAR aligner (29). Differential expression was calculated using DESeq2 v1.18.1 using an FDR-adjusted p -values <0.05. Overrepresentation analysis was performed using a Fisher's exact test to quantify the overlap of differentially expressed genes with the gene sets in the Broad Institute's Molecular Signatures Database (MSigDB). Heatmaps and volcano plots were made with the R packages pheatmap and EnhancedVolcano, respectively.

Automated CUT&RUN Sequencing and analysis

250-500K cells/reaction were collected and washed with Wash Buffer (20 mM HEPES-NaOH pH 7.5, 150 mM NaCl, 0.5 mM Spermidine, Protease Inhibitor) and incubated for 5 min at room temperature with BioMag Plus Concanavalin A-coated magnetic beads (Bangs Laboratories, BP531; 15 uL/ reaction). Supernatant was removed and

beads/cells were resuspended in antibody buffer (20 mM HEPES-NaOH pH 7.5, 150 mM NaCl, 0.5 mM Spermidine, 0.05% Digitonin, 2 mM EDTA, Protease Inhibitor) and antibodies were added (Supplementary Table S1). Samples were incubated 24-48 hours at 4°C then submitted to the Genomics core at the Fred Hutchinson and the Automated CUT&RUN protocol was performed as described

(29)(<https://www.protocols.io/view/autocut-run-genome-wide-profiling-of-chromatin-profile>).

FastQC 0.1.9 (<https://www.bioinformatics.babraham.ac.uk/projects/fastqc/>) was used to examine read quality and paired-end reads were aligned to hg38 using Bowtie2.3.5. Peaks of histone marks were called using MACS2.2.7 with both treatment-only and IgG-controlled modes. Narrow peaks were called and filtered for H3K4me1, H3K4me3, and H3K27ac, while broad peaks were called and filtered for H3K27me3.

For downstream analyses, IgG-controlled narrow peaks were kept if they overlapped with treatment-only peaks from the same sample, q-value is less than 0.01 and fold enrichment is over 2; treatment-only broad peaks were kept if they overlap with IgG-controlled peaks from the same sample, peak width is at least 2 Kbp, q-value is less than 0.01 and fold enrichment is over 2.

For HOXD13, in addition to MACS2 narrow peak calling and peak filtering described above, SEACR was also run with stringent mode. Filtered MACS2 peaks that overlap with SEACR peaks were passed on to the downstream analyses. BEDTools 2.30.0 was used to identify overlapping peaks between marks. Peak annotation and motif analysis was

performed with HOMER 4.11. HOMER was also used to identify TF motifs in peaks. Overlaps of genes were calculated using the Fischer's exact test from the GeneOverlap package and overlaps of genomic sites were calculated using ChIPpeakAnno. Length and number of GGAA/CCTT sites were calculated for overlapped HOXD13 and EWS::FLI1 binding sites within 250bp up and downstream the peak in hg38.

CITE-seq processing and analysis

CITE-seq allows for matched transcript and cell surface antigen profiling of individual cells (38, 39). 500 000 CHLA10 and A673 cells were resuspended in PBS + 1% FBS and spun at 300g for 10 minutes at 4C and then resuspended in 25 uL Biolegend staining buffer (420201, San Diego, CA). 2.5 uL human TruStain FcX (422301, San Diego, CA) was added per sample and incubated at 4C for 10 minutes. Hash-Tag Antibodies, used to label the samples and minimize batch effects, were added at 250 ng/sample (0.5 uL/sample) and incubated at 4C for 30 minutes. Cells were washed twice in 1 mL staining buffer and spun at 300g for 5 minutes at 4C. Samples were pooled 1:1 at 1 000 cells/uL and libraries were generated using the 3' V3 10X Genomics Chromium Controller following the manufacturer's protocol (CG000183, Pleasanton, CA). Final library quality was assessed using the TapeStation 4200 (Agilent, Santa Clara, CA) and libraries were quantified by Kapa qPCR (Roche). Pooled libraries were then subjected to paired-end sequencing according to the manufacturer's protocol (Illumina NovaSeq 6000). Bcl2fastq2 Conversion Software (Illumina) was used to generate de-multiplexed Fastq files and the CellRanger (3.1) Pipeline (10X Genomics) was used to align reads and generate count matrices. Analysis performed using Seurat and Monocle 3. A graph-based

unsupervised clustering approach followed by the nonlinear dimensionality reduction technique, Uniform Manifold Approximation Projection (UMAP) was then used to cluster and visualize the data within each cell line.

Analysis of EWS::FLI1 ChIP-seq for hg38 alignment

Raw fastqs from GEO were downloaded using SRA tools (GSE61953)(2). These were converted to BED files using chromap aligned to hg38 and then into bigwigs using Kent Utilities from the UCSC tools package.

HiChIP data processing

HiChIP Promoter Enhancer chain interactions in A673 WT cells (14) for all the putative “direct” HOXD13-regulated target genes for A673 and CHLA10 cells were interrogated for overlap with HOXD13 binding sites (converted to hg19 using UCSC LiftOver). This was also performed on the nearest genes to shared c-bound EWS::FLI1 and HOXD13 sites.

Supplementary information
Table S1 Supplementary materials

REAGENT or RESOURCE	SOURCE	IDENTIFIER	Concentration
Antibodies			
Rabbit polyclonal anti-FLI1	abcam	Cat# ab15289; RRID:AB_301825	ChIP- 5ug/1x10 ⁶ cells; WB- 5ug/2.5 mL in 5% milk & TBST
Rabbit polyclonal anti-HOXD13	This study	N/A	WB- 1:500 in 5% milk & TBST; ICC- 1:100 (4.6 ug) 10% donkey serum + 0.2% triton & PBS; CUT&RUN: 1:20
Rabbit monoclonal IgG (ICC)	Abcam	Cat# ab172730; RRID:AB_2687931	ICC- 4.6 ug "same as above"
Rabbit monoclonal ant-GAPDH	Cell signaling	Cat# 2118; RRID:AB_561053	WB- 1:1 000 in 5% milk & TBST
Mouse monoclonal anti-GAPDH	Invitrogen	Cat# AM4300; RRID:AB_2536381	WB- 1:13 000 in 5% milk & TBST
Rabbit polyclonal anti-histone H3K27ac (ChIP-RTqPCR)	abcam	Cat# ab4729; RRID:AB_2118291	ChIP- 2ug/1x10 ⁶ cells
Rabbit monoclonal anti-histone H3K27ac (CUT&RUN)	Millipore	Cat# MABE647; RRID:AB_2893037	CnR- 1:50
Rabbit polyclonal anti-histone H3K4me1 (ChIP-RTqPCR)	abcam	Cat# ab8895; RRID:AB_306847	ChIP- 2ug/1x10 ⁶ cells
Rabbit polyclonal anti-histone H3K4me1 (CUT&RUN)	Epicyper	Cat# 13-0040	CnR- 1:100
Rabbit polyclonal anti-histone H3K9me3 (ChIP-RTqPCR)	abcam	Cat# ab8898; RRID:AB_306848	ChIP- 2ug/1x10 ⁶ cells; CnR- 1:100
Rabbit polyclonal anti-histone H3K4me3 (CUT&RUN)	Active motif	Cat# 39159; RRID:AB_2615077	CnR- 1:50
Rabbit monoclonal anti-histone H3K27me3 (CUT&RUN)	Cell Signaling	Cat# 9733; RRID:AB_2616029	CnR- 1:100
Rabbit polyclonal IgG (ChIP-RTqPCR,CUT&RUN)	abcam	Cat# ab37415; RRID:AB_2631996	ChIP- 2-5ug/1 million cells CnR- 1:50
Mouse monoclonal anti-CD73 BB515	BD Pharmingen	Cat# BDB565110; RRID:AB_2739072	Flow- 5 uL/1x10 ⁶ cells
Mouse monoclonal anti-CD271 BB515	BD Pharmingen	Cat# BDB564580; RRID:AB_2738853	Flow- 5 uL/1x10 ⁶ cells
Mouse IgG1, kappa, BB515	BD Pharmingen	Cat# BDB564416; RRID:AB_2721017	Flow- 5 uL/1x10 ⁶ cells
Mouse monoclonal anti-CD73 PE	BD Pharmingen	Cat# BDB561014; RRID:AB_2033967	Flow- 20 uL/1x10 ⁶ cells
Mouse monoclonal anti-CD271 PE	BD Pharmingen	Cat# BDB560927; RRID:AB_10564069	Flow- 20 uL/1x10 ⁶ cells
Mouse IgG1, kappa, PE	BD Pharmingen	Cat# BDB555749; RRID:AB_396091	Flow- 20 uL/1x10 ⁶ cells
TotalSeq-A0251 anti-human hashtag 1 (HTO1)	BioLegend	Cat# 394601; RRID:AB_2750015	CITE- 1 uL/1x10 ⁶ cells
TotalSeq-A0252 anti-human hashtag 2 (HTO2)	BioLegend	Cat# 394603; RRID:AB_2750016	CITE- 1 uL/1x10 ⁶ cells
IRDye 800CW Goat anti-Rabbit IgG Secondary Antibody	LiCor	Cat# 926-32211	WB- 1:10, 00 in TBST
IRDye 680CW Goat anti-Rabbit IgG Secondary Antibody	LiCor	Cat# 926-68071	WB- 1:10 000 in TBST
IRDye 680CW Goat anti-Mouse IgG Secondary Antibody	LiCor	Cat# 926-68070	WB- 1:10 000 in TBST
Donkey anti-Rabbit 488 Secondary	Fisher	Cat# A11034	IF- 1:500

Alexa Fluor 647 Goat anti rabbit IgG	Life Technologies	Cat#:A-21245	ICC- 1:1 000
Deposited data			
Bru-seq, RNA-seq, CUT&RUN, and CITE-seq	This study	GSE182513	N/A
CITE-seq analysis	This study	https://github.com/LawlorLab/HOXD13-Paper	N/A
EWS::FLI1 knockdown bulk RNA-seq	Riggi et al., 2014 (2)	GSE61953	N/A
EWS::FLI1, H3K4me1, H3K4me3, H3K327me3 ChIP-seq in A673 and SKNMC cells and primary tumors.	Riggi et al., 2014 (2)	GSE61953	N/A
ATAC-seq and H3K27ac and H3K4me1 ChIP-seq in MSCs	Riggi et al., 2014 (2)	GSE61953	N/A
EWS::FLI1, H3K4me1 ChIP-seq data and ATAC-seq in MSCs	Boulay et al., 2017 (5)	GSE94275	N/A
EWS::FLI1, H3K4me1, H3K4me3, H3K27me3 ChIP-seq data in MSCs	Boulay et al., 2018 (6)	GSE106925	N/A
H3K27ac and H3K4me1 in Osteosarcoma primary tumors	Morrow et al., 2018 (38)	GSE74230	N/A
H3K27ac and EWS::ETS fusions in EwS cell lines	Orth et al. 2021 (37)	GSE176339; https://hgserver1.amc.nl/cgi-bin/r2/main.cgi?dscope=ESCLA&option=about_dscope	N/A
Single-cell RNA sequencing from A673 shEF xenografts and PDX tumors	Aynaud et al., 2020 (35)	GSE130025	N/A
DbGAP Bulk Patient RNA-seq data	BioProject PRJNA253759 and PRJNA261990	NCBI-phs000768.v1.p1	N/A
HOXD13 expression in cell lines (CCLE)	Barretina et al. 2012/2019 (32)	https://depmap.org/portal/ccle/	N/A
HOXD13 expression in pediatric tumors (Pediatric Pan Cancer (DFKZ).	Groebner et al. 2018 (33)	https://hgserver1.amc.nl/cgi-bin/r2/main.cgi?dscope=DKFZ_PED&option=about_dscope	N/A
Oligonucleotides			Size (bp) & location hg19
Taqman probe human 18S (housekeeping)	Thermo	Hs03003631_g1	69 bp
Taqman probe human B2M	Thermo	Hs00984230_m1	81 bp
Taqman probe human HOXD13	Thermo	Hs00968515_m1	102 bp
Taqman probe human HOXD11	Thermo	Hs00360798_m1	133 bp
Taqman probe human HOXD10	Thermo	Hs00157974_m1	61 bp
Taqman probe EWS::FLI1 type 1 fusion	Thermo	Hs03024497_ft	80 bp
Taqman probe NR0B1	Thermo	Hs00230864_m1	92 bp
Taqman probe VRK1	Thermo	Hs00177470_m1	85 bp
VRK1 GGAA enhancer- <i>EWS::FLI1 binding</i> F: (5'ACTCGGCTTTTTGCAACTTC 3')	Riggi et al. 2014 (2)	N/A	135; chr14:97681757-97681891
VRK1 GGAA enhancer- <i>EWS::FLI1 binding</i> R: (5' CCTCTTGCCTTCCTTCCTTC 3')	Riggi et al. 2014 (2)	N/A	
VRK1 GGAA enhancer- <i>histone marks</i> F: (5' CGATGGGTGATCAATGAGTG 3')	This study	N/A	236; chr14:97681017-97681252
VRK1 GGAA enhancer- <i>histone marks</i>	This study	N/A	

R: (5' AAGAGAGCTTGGGGAGGAAG 3')			
Negative control region in chr2 F: (5' ATGGTGATTCTCAGCCTCCA 3')	This study	N/A	107; chr2:176644216- 176644322
Negative control region in chr2 R: (5' TGCAGGATTTAAGGGAACCA 3')	This study	N/A	
PHE- <i>EWS::FLI1</i> binding F: (5' CTCCTTGCTTCCTTCCTTC 3')	This study	N/A	104; chr2:176268617- 176268720
PHE- <i>EWS::FLI1</i> binding R: (5' TACCCAGAACTGGCACACA 3')	This study	N/A	
PHE- <i>histone marks</i> F: (5' AAATGGCATGATCACTTTTGTG 3')	This study	N/A	92; chr2:176269105- 176269196
PHE- <i>histone marks</i> R: (5' CTTTCTCTGCCCCAGTTTT 3')	This study	N/A	
SOX2 GGAA enhancer F: (5' GAAGTGCACCCTATGCCAGT 3')	Riggi et al. 2014 (2)	N/A	104; chr3:181901578- 181901681
SOX2 GGAA enhancer R: (5' TCCTCTGTGGGGGTTATCCA 3')	Riggi et al. 2014 (2)	N/A	
sgRNAs for Crispr			
Negative control-chr1 non-targeting site sgRNA F: (5' CACCG CCAAACATTCCAGCTATCCA 3') *red indicates restriction cut sites	Fulco et al. 2016	N/A	
Negative control-chr1 non-targeting site sgRNA R: (5' AAACT GGATAGCTGGAATGTTTGGC 3') *red indicates restriction cut sites	Fulco et al. 2016	N/A	
SOX2 GGAA sgRNA F: (5' CACCT TATCCATCTAACAGGTGGG 3')	Boulay et al. 2018 (6)	N/A	
SOX2 GGAA sgRNA R: (5' AAAC CCCACCTGTTAGATGGATAA 3')	Boulay et al. 2018 (^)	N/A	
PHE_1 sgRNA F: (5' CACCG TGTCCCTAAGTATACAGATA 3')	This study	N/A	
PHE_1 sgRNA R: (5' AACT ATCTGTATACTTAGGGACAC 3')	This study	N/A	
PHE_2 shRNA F: (5' CACCG GCCCTACTATCTCTCAGTGA3')	This study	N/A	
PHE_2 sgRNA R: (5' AACT CACTGAGAGATAGTAGGGCC 3')	This study	N/A	
PHE_3 sgRNA F: (5' CACCG ATGTCATGTATAATCCTGCA 3')	This study	N/A	
PHE_3 sgRNA R: (5' AACT TAGATTACAAATTCCGTGCC 3')	This study	N/A	
Recombinant DNA			
pCD/NL-BH*DDD	addgene	Cat# 17531	N/A
pMD2.G	addgene	Cat# 12259	N/A
pLKO.1 non-targeting shRNA	Sigma	Cat# SHC002	N/A
pLKO.1 FLI1-targeting shRNA	Sigma	TRCN0000005322	N/A
pTripz shNS	Horizon-Dharmacon	RHS4743	N/A
pTripz shHOXD13 #1	Horizon-Dharmacon	RHS4696- 200755961, clone: V3THS_321416	N/A
pTripz shHOXD13 #2	Horizon-Dharmacon	RHS4696- 200680827, clone: V2THS_93475).	N/A
pCLS-EGFP empty	This study	N/A	N/A
EWS::FLI1-V5-2A-EGFP	This study	N/A	N/A

pLIV empty	M. Rivera Laboratory, MGH, Boston, MA, USA	Riggi et al., 2014	N/A
pLIV EWS::FLI1	M. Rivera Laboratory, MGH, Boston, MA, USA	Riggi et al., 2014	N/A
UCOE-SFFV-dCas9-KRAB-BFP	Addgene	85969	N/A
pHR-SFFV-KRAB-dCas9-P2A-mCherry	Addgene	60954	N/A
UCOE-SFFV-KRAB-dCas9-P2A	This study	N/A	N/A
sgOpti	Addgene	85681	N/A
Software			
FastQC	Babraham Institute	https://www.bioinformatics.babraham.ac.uk/projects/fastqc/	N/A
Trim Galore	Babraham Institute	https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/	N/A
STAR	https://github.com/alexdobin/STAR	DOI: 10.1093/bioinformatics/bts635	N/A
DeSeq2 v1.18.1	https://bioconductor.org/packages/release/bioc/html/DESeq2.html	https://doi.org/10.1186/gb-2010-11-10-r106	N/A
MsigDB	https://www.gsea-msigdb.org/gsea/msigdb/	doi: 10.1093/bioinformatics/btr260	N/A
pheatmap	https://www.rdocumentation.org/packages/pheatmap/versions/1.0.12/topics/pheatmap		N/A
EnhancedVolcano	https://bioconductor.org/packages/devel/bioc/vignettes/EnhancedVolcano/inst/doc/EnhancedVolcano.html		N/A
Bowtie2.3.5	http://bowtie-bio.sourceforge.net/bowtie2/index.shtml	https://doi.org/10.1038/nmeth.1923	N/A
MACS2.2.7	https://github.com/macs3-project/MACS	DOI: 10.1186/gb-2008-9-9-r137	N/A
BEDTools 2.30.0	https://bedtools.readthedocs.io/en/latest/	https://doi.org/10.1093/bioinformatics/btq033	N/A
SEACR	https://github.com/FredHutch/SEACR	https://doi.org/10.1186/s13072-019-0287-4	N/A
HOMER 4.11	http://homer.ucsd.edu/homer/	DOI: 10.1016/j.molcel.2010.05.004	N/A
GeneOverlap	https://bioconductor.org/packages/release/bioc/html/GeneOverlap.html		N/A
ChIPpeakAnno	https://bioconductor.org/packages/release/bioc/html/ChIPpeakAnno.html		N/A